Boston Scientific invested $1.5 billion for a 34% equity stake in MiRus LLC, a company specializing in advanced biomaterials and medical implants. The deal includes an exclusive option for Boston Scientific to acquire MiRus's proprietary TAVR system, which uses a nickel-free rhenium alloy, for $3 billion if specific clinical and regulatory milestones are met. The SIEGEL TAVR system is currently undergoing the STAR pivotal trial to evaluate its safety and efficacy in treating severe aortic stenosis, featuring an open-cell frame design and a delivery sheath about 50% smaller than currently available options to reduce vascular injury risk. The partnership aims to support Boston Scientific's interventional cardiology portfolio with a less invasive treatment option, and the agreement also grants future rights to acquire additional mitral and tricuspid valve assets from MiRus if the option is exercised.
Boston Scientific CorpBoston Scientific gains exclusive option to acquire MiRus's proprietary TAVR system with advanced nickel-free rhenium alloy and smaller delivery sheath, enhancing its interventional cardiology portfolio.
Alibaba Group Holding LtdMiRus receives $1.5 billion investment from Boston Scientific for a 34% stake, with potential $3 billion acquisition option for its TAVR system.